Adaptimmune Therapeutics plc ADR

Adaptimmune Therapeutics plc is a biopharmaceutical company specializing in innovative cell therapies for cancer treatment. The company develops engineered T cell therapies that harness patients' own immune cells to target and destroy cancer cells, utilizing advanced T cell receptor technology to strengthen natural immune responses. Adaptimmune's therapeutic approach focuses on solid tumors and hematological malignancies, including conditions such as synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer. The company has achieved significant regulatory milestones, including FDA accelerated approval for its lead therapy and breakthrough therapy designations for additional candidates. Operating as a commercial-stage biopharmaceutical company with operations in the United States and headquarters in Philadelphia and Milton Park, Adaptimmune represents a frontier in cancer immunotherapy by enabling personalized cellular treatments designed to combat some of the most challenging malignancies.